RxDoctor Payments Data

Amy Robinson, MD

Family Medicine · Lewes, DENPI 1063407328

Payments from drug & device makers

$1,283in general payments, 2019–2025

Across 86 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$188
  • AstraZeneca$127
  • Amgen$120
  • Novartis$101
  • Pfizer$98
  • Boehringer Ingelheim$89
  • plus $560 from 15 others

What the payments were for

  • Food & beverage$1,25298%
  • Education$312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,283 in reported general payments places this provider in the 70th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$450,325
Medicare patients
819
Services billed
5,277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$249,937
JardianceEmpagliflozin103$138,785
TrulicityDulaglutide31$60,393
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$56,788
LinzessLinaclotide62$48,456
EliquisApixaban39$46,377
MounjaroTirzepatide28$40,524
Breo ElliptaFluticasone/Vilanterol49$38,437
MyrbetriqMirabegron16$19,033
JanuviaSitagliptin Phosphate11$17,333
Atorvastatin Calcium921$13,426
Repatha SureclickEvolocumab11$13,413
Rosuvastatin Calcium569$12,162
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$12,074
FarxigaDapagliflozin Propanediol21$11,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$188$249,937131 claims
Boehringer IngelheimJardiance$89$138,785103 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$31$107,29999 claims
Lilly USA, LLCTrulicity, Mounjaro$56$100,91859 claims
AbbVieLinzess, Synthroid$82$57,049226 claims
PfizerEliquis, Premarin$98$52,68452 claims
Astellas Pharma US IncMyrbetriq$18$19,03316 claims
MerckJanuvia$38$17,33311 claims
AstraZenecaFarxiga$127$11,56921 claims
Kowa Pharmaceuticals America, Inc.Bystolic$14$4,82311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 352 family medicine providers in Delaware.

Other family medicine in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →